EssilorLuxottica Acquires RetinAI to Advance AI in Eye Health
EssilorLuxottica has acquired RetinAI, a health technology company specializing in AI and data management for eyecare. The acquisition strengthens the group's med-tech offerings.
Eyewear giant EssilorLuxottica announced the acquisition of RetinAI, a health technology company focused on AI and data management in eyecare. This move significantly bolsters the Group's medical technology capabilities.
RetinAI develops advanced software powered by machine learning and computer vision. Its solutions streamline clinical workflows and research, providing AI-driven insights to healthcare professionals for enhanced patient care. The company's flagship platform, RetinAI Discovery, which holds FDA 510(k) clearance and CE marking, uses AI to analyze retinal images, aiding in the diagnosis and monitoring of conditions such as age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy.
In addition to clinical applications, RetinAI partners with pharmaceutical companies and research organizations, leveraging real-world data to accelerate clinical studies. EssilorLuxottica CEO Francesco Milleri highlighted the acquisition as a key step in the company's med-tech strategy, aiming to build a comprehensive digital patient journey.
The integration of RetinAI's technology is expected to enable EssilorLuxottica to translate clinical data into actionable insights, leading to faster diagnoses and more effective disease management, marking a new phase in the company's healthcare advancements.